Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 2730 for:    Neoplasms | Neuroendocrine Tumors

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01099540
Recruitment Status : Completed
First Posted : April 7, 2010
Last Update Posted : December 29, 2015
Sponsor:
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center

Brief Summary:
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumor Drug: Pazopanib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Study Start Date : April 2010
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Pazopanib

Arm Intervention/treatment
Experimental: Pazopanib Drug: Pazopanib
Pazopanib 800 mg qd daily




Primary Outcome Measures :
  1. response rate [ Time Frame: 1~2 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion Criteria:

  • poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01099540


Locations
Layout table for location information
Korea, Republic of
Samsung Cancer Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Samsung Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jeeyun Lee, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01099540     History of Changes
Other Study ID Numbers: 2009-09-090
First Posted: April 7, 2010    Key Record Dates
Last Update Posted: December 29, 2015
Last Verified: December 2015

Keywords provided by Jeeyun Lee, Samsung Medical Center:
neuroendocrine tumor

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue